Revimmune Overview
- Founded
- 2006

- Status
- Acquired/Merged
- Employees
- 2

- Latest Deal Type
- M&A
- Financing Rounds
- 3
Revimmune General Information
Description
Developer of therapies for autoimmune diseases. The Company's lead antineoplastic technology employs a bioengineered poliovirus construct and targets cancerous central nervous cells with great specificity recombinant poliovirus therapy has the potential to significantly reduce or eliminate current chemotherapy side-effects while completely destroying abnormal cancerous tissue.
Contact Information
- 324 South Hyde Park Avenue
- Suite 350
- Tampa, FL 33606
- United States
Revimmune Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Revimmune‘s full profile, request access.
Request a free trialRevimmune Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Frank O'Donnell | Director & Officer | ||
Richard Jones | Co-Founder | ||
Robert Brodsky | Co-Founder |
Revimmune Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialRevimmune Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Revimmune‘s full profile, request access.
Request a free trial